DHR Stock Price Today (September 2026) — Danaher Corporation Analysis & Key Metrics 2026-09-03
Danaher Corporation (DHR) is trading at $211.03, up 0.53% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $227.96 (8.0% upside).
- Volatility remains elevated (27.76% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.50% YoY) alongside significant competitive pressures.
DHR Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Danaher Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $175.42B
P/E Ratio
Forward P/E: 22.97
Revenue Growth
Year over Year
Analyst Target
+8.0% upside potential
Key Investor Questions About DHR
What investors need to know before buying
Based on current market data, DHR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 52.20)
- Fundamentals say: Caution warranted (high leverage concerns)
DHR's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DHR investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $27.86B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, DHR stock traded between $160.93 and $242.80—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.76% annualized volatility and β=0.86, the stock exhibits moderate correlation to market moves—making DHR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks. Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that...
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
Is Danaher Stock Underperforming the Nasdaq?
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Profitable Stock on Our Buy List and 2 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
3 Industrials Stocks with Questionable Fundamentals
Even if they go mostly unnoticed, industrial businesses are the backbone of our country. But they are at the whim of volatile macroeconomic factors that influence capital spending (like interest rates), and the market seems convinced that demand will slow. Due to this bearish outlook, the industry has tumbled by 2.5% over the past six months. This performance is a far cry from the S&P 500’s 10.8% ascent.
Explore More Analysis for DHR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Danaher Corporation
Danaher Corporation (DHR) is currently trading at $211.03. The RSI (14-day) is at 52.2, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $227.96 implies 8.0% upside from current levels. Volatility is moderate at 27.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Danaher Corporation (DHR): The trailing P/E ratio is 37.55, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 22.97, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.41, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.82. Price-to-Sales is 5.91. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering DHR, the consensus price target is $227.96. This represents a 8.0% upside from the current price of $211.03. The range spans from a low target of $195.00 to a high target of $310.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Danaher Corporation (DHR) pays a dividend with a current yield of approximately 76.00%. The annualized dividend rate is $1.44 per share. The payout ratio is 25.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-26T00:00:00.000Z.
Key risks for Danaher Corporation (DHR) investors include: 1. Moderate volatility (27.8% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Danaher Corporation's (DHR) current debt and financial health profile: Total debt stands at $27.86B. The debt-to-equity ratio is 52.97, which is moderate and generally manageable for most companies. The current ratio is 1.65, indicating strong short-term liquidity. The quick ratio is 1.15. The company holds $4.35B in cash and equivalents. Free cash flow is positive at $4.33B, providing a cushion for debt servicing and shareholder returns.